glp 1 and gila monster The GLP-1 Story... (a GoggleDocs Podcast) Gila Monster Venom: The Unexpected

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect

We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound)

Lifestyle modification and nutrition-based approaches are regarded as the cornerstone strategies for treating pediatric obesity

Both classes have cardiovascular and kidney disease benefits, but while GLP-1s have far superior weight-loss results, they are also over 1.5 times more expensive at list price than SGLT2s

Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection

Please join us for this webinar